Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
LifeNet Health is currently managing 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 7 actions are distributed among 7 distinct examiners, resulting in a distribution where each active case is assigned to an individual reviewer. This structure indicates that each of the company's biotechnology matters is receiving an independent evaluation.
The workload is spread across 6 distinct art units, which shows a high degree of technical variety within the 7 pending office actions. BERKE-SCHLESSEL, DAVID W is the busiest examiner for the company, with 1 pending office action currently assigned. This single action represents 1 of the 7 total pending actions for the portfolio.
Because there are 7 distinct examiners and 6 distinct art units for 7 pending office actions, the company's prosecution environment is highly fragmented. Practitioners must navigate the specific requirements of 6 different art units. Since the busiest examiner, BERKE-SCHLESSEL, DAVID W, only handles 1 case, there is no significant concentration of workload with any single individual, requiring a broad strategy to manage the diverse examiner pool.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §102 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| HERBERT, MADISON TAYLOR | 1 | 59.1% | +53.7% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| ALEMAN, SARAH WEBB | 1 | 62.2% | +23.6% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 62d |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | — |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | — |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17088860 | ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES | VAN BUREN, LAUREN K | 72d overdue |
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 62d |
| 18757079 | CROSSLINKED SOFT TISSUE GRAFT AND METHODS OF USE THEREOF | BERKE-SCHLESSEL, DAVID W | — |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | — |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | — |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | — |
| 17603661 | BIRTH TISSUE-DERIVED PRODUCTS AND PREPARATION AND USES THEREOF | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1651 | 1 |
| 1758 | 1 |
| 3774 | 1 |
| 1631 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18757079 | CROSSLINKED SOFT TISSUE GRAFT AND METHODS OF USE THEREOF | BERKE-SCHLESSEL, DAVID W | 1651 | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | 1758 | §102§103 | Final Rejection | — | Pending | Nov 15, 2022 |
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 1638 | §102§103§112 | Non-Final OA | 62d | Pending | Apr 28, 2022 |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | 3774 | §101§103 | Final Rejection | — | Pending | Mar 15, 2022 |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2021 |
| 17603661 | BIRTH TISSUE-DERIVED PRODUCTS AND PREPARATION AND USES THEREOF | STAVROU, CONSTANTINA E | 1632 | §102 | Final Rejection | — | Pending | Oct 14, 2021 |
| 17088860 | ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES | VAN BUREN, LAUREN K | 1638 | §112DP | Final Rejection | 72d overdue | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLifeNet Health has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
David W Berke-Schlessel has the most, with 1 of LifeNet Health's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
